Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; and Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations. It also offers bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Minnebro for the treatment of hypertension; and Bryxta for non-small cell lung cancer. The company's partners programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney, and other diseases. It is also developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
KOZARICH JOHN W | Director | Feb 22 | Option Exercise | 10.12 | 2,500 | 25,300 | 29,708 | Feb 23 05:18 PM | Davis Todd C | Director | Feb 11 | Option Exercise | 195.91 | 2,474 | 484,681 | 50,152 | Feb 12 06:23 PM | Davis Todd C | Director | Feb 10 | Sale | 213.14 | 5,083 | 1,083,410 | 47,678 | Feb 12 06:23 PM | Sabba Stephen L | Director | Feb 09 | Option Exercise | 11.32 | 14,670 | 166,138 | 39,101 | Feb 11 04:06 PM | Sabba Stephen L | Director | Feb 09 | Sale | 208.53 | 14,670 | 3,059,123 | 24,431 | Feb 11 04:06 PM | HIGGINS JOHN L | Chief Executive Officer | Feb 05 | Option Exercise | 12.16 | 114,666 | 1,394,017 | 346,030 | Feb 09 06:08 PM | HIGGINS JOHN L | Chief Executive Officer | Feb 05 | Sale | 203.40 | 54,666 | 11,119,239 | 286,030 | Feb 09 06:08 PM | FOEHR MATTHEW W | President and COO | Feb 04 | Option Exercise | 23.07 | 45,547 | 1,050,890 | 212,745 | Feb 05 05:03 PM | FOEHR MATTHEW W | President and COO | Feb 04 | Sale | 176.86 | 44,547 | 7,878,582 | 168,198 | Feb 05 05:03 PM | Berkman Charles S | SVP, Gen. Counsel & Secretary | Feb 04 | Sale | 178.50 | 18,097 | 3,230,376 | 28,906 | Feb 05 05:03 PM | HIGGINS JOHN L | Chief Executive Officer | Jan 27 | Option Exercise | 17.66 | 70,000 | 1,236,400 | 283,422 | Jan 27 07:04 PM | Davis Todd C | Director | Jan 27 | Option Exercise | 113.50 | 2,456 | 278,756 | 52,761 | Jan 27 07:02 PM | HIGGINS JOHN L | Chief Executive Officer | Jan 27 | Sale | 182.00 | 40,000 | 7,280,000 | 243,422 | Jan 27 07:04 PM | HIGGINS JOHN L | Chief Executive Officer | Jan 25 | Option Exercise | 14.47 | 50,000 | 723,500 | 285,310 | Jan 27 07:04 PM | HIGGINS JOHN L | Chief Executive Officer | Jan 25 | Sale | 159.00 | 50,000 | 7,950,000 | 235,310 | Jan 27 07:04 PM | HIGGINS JOHN L | Chief Executive Officer | Dec 08 | Option Exercise | 10.05 | 14,657 | 147,303 | 236,770 | Dec 09 06:12 PM | HIGGINS JOHN L | Chief Executive Officer | Nov 09 | Option Exercise | 10.05 | 20,000 | 201,000 | 224,571 | Nov 10 07:41 PM | Patel Sunil | Director | Nov 02 | Buy | 82.52 | 1,000 | 82,520 | 28,190 | Nov 04 04:19 PM | FOEHR MATTHEW W | President and COO | Aug 24 | Option Exercise | 21.92 | 78 | 1,710 | 155,491 | Aug 25 07:10 PM | FOEHR MATTHEW W | President and COO | Aug 24 | Sale | 110.89 | 78 | 8,649 | 155,413 | Aug 25 07:10 PM | FOEHR MATTHEW W | President and COO | Aug 21 | Option Exercise | 20.38 | 8,015 | 163,338 | 162,638 | Aug 25 07:10 PM | FOEHR MATTHEW W | President and COO | Aug 21 | Sale | 112.88 | 7,225 | 815,541 | 155,413 | Aug 25 07:10 PM | HIGGINS JOHN L | Chief Executive Officer | Jul 07 | Option Exercise | 70.01 | 4,315 | 302,098 | 204,571 | Jul 09 04:28 PM | Berkman Charles S | SVP, Gen. Counsel & Secretary | Jun 04 | Sale | 118.59 | 11,146 | 1,321,775 | 40,877 | Jun 05 04:07 PM | FOEHR MATTHEW W | President and COO | Mar 13 | Option Exercise | 21.92 | 2,000 | 43,840 | 157,449 | Mar 13 06:33 PM |
|